This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
New Immuno-Oncology Solutions (NIOS): Aligning Stakeholders in the Biotech Industry
Vroom, Govert; Maribel Berges; Sastre Boquet, IsaacCase SM-1701-EEntrepreneurship, Innovation and Change, StrategyThis case focuses on a small biotech company (NIOS), located in Barcelona, Spain, that is developing a new immune-oncology product for treating pancreatic cancer. The drug that the company is developing has recently finished Phase I of clinical trials successfully and is now preparing for Phase II and III. At this point, the CEO is approached by her former PhD director, a university professor, who asks if the company is interested in licensing a ...Starting at €8.20
-
Suntory Beverage & Food Spain: La sostenibilidad como estrategia competitiva
Garrido Martinez, E.; Rodríguez Bouzo, S.; Valderrrama, B.Teaching Note IIST-DGITN-336Innovation and ChangeLa función de la sostenibilidad no es otra que conectar los intereses de la empresa con las expectativas de la sociedad. El impacto de la pandemia hace necesario un nuevo enfoque que contemple qué nuevas tendencias afectarán a la demanda de los productos y al suministro de las materias primas, y más importante aún si cabe, qué demandarán los clientes, empleados, proveedores e inversores del negocio en el futuro. Y todo ello, bajo la premisa de eq...Starting at €0.00
-
New Immuno-Oncology Solutions (NIOS) - Teaching Note: Aligning stakeholders in the biotech industry
Vroom, Govert; Maribel Berges; Sastre Boquet, IsaacTeaching Note SMT-136-EEntrepreneurship, Innovation and Change, StrategyThis case focuses on a small biotech company (NIOS), located in Barcelona, Spain, that is developing a new immune-oncology product for treating pancreatic cancer. The drug that the company is developing has recently finished Phase I of clinical trials successfully and is now preparing for Phase II and III. At this point, the CEO is approached by her former PhD director, a university professor, who asks if the company is interested in licensing a ...Starting at €0.00